Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Market Closed 01-09 16:00:00 EST

5.85

-0.10

-1.68%

盘后5.90

+0.05+0.84%

19:08 EST

High6.09	Low5.80	Vol1.32M
Open6.01	D1 Closing5.95	Amplitude4.96%
Mkt Cap813.88M	Tradable Cap553.14M	Total Shares139.13M
T/O7.78M	T/O Rate1.39%	Tradable Shares94.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":5.85,"timestamp":1767992400000,"preClose":5.95,"halted":0,"volume":1317026,"hourTrading":{"tag":"盘后","latestPrice":5.8991,"preClose":5.85,"latestTime":"19:08 EST","volume":23750,"amount":138979.4655,"timestamp":1768003731522},"delay":0,"floatShares":94554590,"shares":139125032,"eps":-3.622804,"marketStatus":"Market Closed","change":-0.1,"latestTime":"01-09 16:00:00 EST","open":6.012,"high":6.09,"low":5.795,"amount":7781534.856764,"amplitude":0.04958,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.622804,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":5.95,"preHourTrading":{"tag":"盘前","latestPrice":6,"preClose":5.95,"latestTime":"09:28 EST","volume":381,"amount":2286.299847,"timestamp":1767968931065},"postHourTrading":{"tag":"盘后","latestPrice":5.8991,"preClose":5.85,"latestTime":"19:08 EST","volume":23750,"amount":138979.4655,"timestamp":1768003731522},"volumeRatio":0.7312936295310354,"impliedVol":0.8638,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2601837860","title":"Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837860","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837860?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647140,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Marianne De Backer is scheduled to present on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Vir Biotechnology website and archived for 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbrmbh5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4139","BK4568","BK4585"],"gpt_icon":0},{"id":"2601319968","title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601319968","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601319968?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:02","pubTimestamp":1767639770,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6hGHvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4535","VIR","BK4585"],"gpt_icon":0},{"id":"2595479056","title":"Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2595479056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595479056?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:43","pubTimestamp":1767102180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2025 08:43 ET (13:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4568","BK4139","VIR"],"gpt_icon":0},{"id":"2592995830","title":"Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592995830?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:06","pubTimestamp":1765922771,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has appointed Minnie Kuo as Chief Operating Officer, effective immediately. Kuo joined the company in September 2023 as Chief Development Officer and has over 20 years of experience in biotechnology and pharmaceuticals, with prior leadership roles at Vir Biotechnology, Nektar Therapeutics, and Gilead Sciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL3FFM7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4583","LU1674673691.USD","LU2468319806.SGD","LU1430594728.SGD","VIR","LU2089984988.USD","BK4566","LU2087621335.USD","IE00B7SZLL34.SGD","LU0109394709.USD","NKTR","LU0058720904.USD","BK4007","SG9999015978.USD","IE00B19Z3581.USD","BK4532","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU1585245621.USD","LU1571399168.USD","LU1066051498.USD","LU2324357040.USD","BK4585","IE0002270589.USD","BK4535","LU0889565916.HKD","BK4588","LU1066053197.SGD","LU1839511570.USD","BK4550","IE00BSNM7G36.USD","LU0882574055.USD","IE00B3T34201.USD","BK4139","LU1674673428.USD","LU0289739699.SGD","SG9999015986.USD","BK4578","IE00BKVL7J92.USD","LU0114720955.EUR","LU0823416689.USD","LU1778281490.HKD","PLRX","SG9999015945.SGD","GILD","SG9999015952.SGD","BK4568"],"gpt_icon":0},{"id":"2592937970","title":"Vir Biotechnology Grants Norgine Exclusive License for Hepatitis Delta Treatment in Europe, Australia, and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937970","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937970?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:06","pubTimestamp":1765919161,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. announced that it has granted Norgine Pharma UK Limited an exclusive commercial license for the combination of tobevibart and elebsiran, an investigational treatment for chronic hepatitis delta, in Europe, Australia, and New Zealand. Under the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and is eligible for up to EUR 495 million in clinical, regulatory, and sales milestones, as well as tiered royalties on net sales in Norgine's licensed territory. Vir Biotechnology will retain commercialization rights for the products in the United States and other markets outside Greater China. The agreement also includes a global cost-sharing arrangement for ongoing clinical development, with Norgine contributing approximately 25% of future external costs related to the ECLIPSE registrational program. The transaction in certain jurisdictions is subject to regulatory approvals.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL5Kvb1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4568","BK4585","BK4139","BK4535"],"gpt_icon":0},{"id":"2592937210","title":"Vir Biotechnology Inc - Norgine to Contribute 25% of Eclipse Program Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937210?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4568","VIR","BK4139","BK4535"],"gpt_icon":0},{"id":"2592893724","title":"Vir Biotechnology- Expects Current Cash, Cash Equivalents and Investments Will Be Extended Into Q4 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2592893724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592893724?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4568","BK4585","BK4139","BK4535"],"gpt_icon":0},{"id":"2592379599","title":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing Eclipse Clinical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2592379599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592379599?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4568","BK4139","BK4535","VIR"],"gpt_icon":0},{"id":"2592214937","title":"Vir Biotechnology - to Receive EUR 55 Mln Initial Reimbursement Payment Upon Closing , EUR 495 Mln in Clinical, Regulatory and Sales Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2592214937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592214937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4535","BK4568","BK4585","BK4139"],"gpt_icon":0},{"id":"2589332882","title":"Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332882","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589332882?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:32","pubTimestamp":1765189975,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders may have reason to be concerned, as several insiders sold their...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4568","BK4139","BK4535","VIR","BK4585"],"gpt_icon":0},{"id":"2588060158","title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588060158","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588060158?lang=en_us&edition=fundamental","pubTime":"2025-12-03 08:48","pubTimestamp":1764722917,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL759zP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4568","VIR","BK4139","BK4535"],"gpt_icon":0},{"id":"2588031447","title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031447","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588031447?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:30","pubTimestamp":1764624642,"startTime":"0","endTime":"0","summary":"SVF Endurance  Ltd has reported a disposal of common shares of Vir Biotechnology Inc. According to the filing, other reporting beneficial owners include SOFTBANK VISION FUND  L.P. and SB INVESTMENT ADVISERS  LTD. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3S9st7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","VIR","BK4585","BK4139"],"gpt_icon":0},{"id":"1187950486","title":"Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=1187950486","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187950486?lang=en_us&edition=fundamental","pubTime":"2025-12-01 23:25","pubTimestamp":1764602721,"startTime":"0","endTime":"0","summary":"Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.Vinay Prasad, a top FDA official, blamed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"de4e5ce05b2acd5962228944615f4d01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","VIR","AMGN","BNTX","HIMS","REGN","AZN","PCVX","MRNA","BIIB","NVAX"],"gpt_icon":0},{"id":"2586298319","title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298319","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586298319?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:31","pubTimestamp":1764192704,"startTime":"0","endTime":"0","summary":"SVF Endurance  Ltd reported a disposal of common shares of Vir Biotechnology Inc., according to a recent SEC Form 4 filing. Other reporting beneficial owners include SoftBank Vision Fund  L.P. and SB Investment Advisers  Ltd, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9s0jkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4568","BK4585","VIR","BK4139"],"gpt_icon":0},{"id":"2585870140","title":"H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585870140","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585870140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746531,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology yesterday and set a price target of $15.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"2584975547","title":"Vir Biotechnology CEO to Join Evercore Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975547?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:05","pubTimestamp":1763586352,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. announced that Chief Executive Officer Marianne De Backer will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3 in Miami, Florida. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL5tkKGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVR","BK4585","VIR","BK4568","BK4139","BK4127","BK4535"],"gpt_icon":0},{"id":"2582861349","title":"Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582861349?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:35","pubTimestamp":1762925728,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Buy rating on Vir Biotechnology yesterday and set a price target of $31.00. The company’s shares closed yes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"1127241931","title":"Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1127241931","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127241931?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:20","pubTimestamp":1762888830,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"1190163920","title":"Stock Track | Vir Biotechnology (VIR) Soars 5.03% on Bullish Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1190163920","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190163920?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:20","pubTimestamp":1762888830,"startTime":"0","endTime":"0","summary":"Shares of Vir Biotechnology, Inc. (VIR) are surging in intraday trading, with the stock price soaring 5.03%. This significant uptick comes on the heels of bullish analyst ratings from two major...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"2582366676","title":"Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366676?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:18","pubTimestamp":1762863502,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Vir Biotechnology, with a price target of $20.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.1069},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0354},{"period":"1year","weight":-0.5313},{"period":"ytd","weight":-0.0299}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.405226},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037395},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.121524},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.08783},{"month":5,"riseRate":0.666667,"avgChangeRate":0.058008},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction